Patent ID: 11957739
Assignee: DANA-FARBER CANCER INSTITUTE, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  G | IPC A  G

Claim 4:
5. The method of claim 4, wherein
a) the immunotherapy is cell-based;
b) the immunotherapy comprises a cancer vaccine and/or virus;
c) the immunotherapy inhibits an immune checkpoint, optionally wherein the immune checkpoint is selected from the group consisting of CTLA-4, PD-1, VISTA, B7-H2, B7-H3, PD-L1, B7-H4, B7-H6, ICOS, HVEM, PD-L2, CD160, gp49B, PIR-B, KIR family receptors, TIM-1, TIM-3, TIM-4, LAG-3, GITR, 4-IBB, OX-40, BTLA, SIRPalpha (CD47), CD48, 2B4 (CD244), B7.1, B7.2, ILT-2, ILT-4, TIGIT, HHLA2, butyrophilins, and A2aR; and/or
d) the cancer therapy is selected from the group consisting of radiation, a radiosensitizer, and a chemotherapy.